← Back to Clinical Trials
Recruiting Phase 4 NCT07190495

NCT07190495 Ginger to Prevent Nausea and Vomiting After Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07190495
Status Recruiting
Phase Phase 4
Sponsor University Tunis El Manar
Condition Postoperative Nausea and Vomiting
Study Type INTERVENTIONAL
Enrollment 102 participants
Start Date 2025-07-05
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
GingerPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 102 participants in total. It began in 2025-07-05 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate whether preoperative oral administration of ginger (800 mg, given 2 hours before surgery) reduces the incidence and severity of postoperative nausea and vomiting (PONV) within the first 24 hours after laparoscopic cholecystectomy.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years. * Scheduled for elective laparoscopic cholecystectomy under general anesthesia. * American Society of Anesthesiologists (ASA) physical status I-III. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Known allergy or hypersensitivity to ginger * Documented history of bleeding disorders or current treatment with anticoagulant agents * History of severe postoperative nausea and vomiting or an Apfel score of 4 * Administration of antiemetic drugs or corticosteroids during the preoperative period * Pregnancy or breastfeeding * Active gastrointestinal or liver disease

Contact & Investigator

Central Contact

Ibtissem BEN TALEB, M.D.

✉ ibtissem.bentaleb@fmt.utm.tn

📞 +216 23 133 748

Frequently Asked Questions

Who can join the NCT07190495 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Nausea and Vomiting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07190495 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07190495 currently recruiting?

Yes, NCT07190495 is actively recruiting participants. Contact the research team at ibtissem.bentaleb@fmt.utm.tn for enrollment information.

Where is the NCT07190495 trial being conducted?

This trial is being conducted at Nabeul, Tunisia.

Who is sponsoring the NCT07190495 clinical trial?

NCT07190495 is sponsored by University Tunis El Manar. The trial plans to enroll 102 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology